ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "B cells"

  • 2017 American Transplant Congress

    Inhibition of Memory T Cell Alloresponses by TIM-1+ B Cells.

    B. Gonzalez-Nolasco, H. Tector, J. Markmann, G. Benichou.

    Department of Surgery, Center for Transplantation Sciences, Massachusetts General Hospital/Harvard Medical School, Boston, MA

    Background:Alloreactive memory T cells mediate accelerated rejection of allografts and prevent tolerance induction. While regulatory B cells (Bregs) can promote tolerance induction through suppression of…
  • 2017 American Transplant Congress

    Characterization of Human Plasma Cell Proteasome Adaptations to Proteasome Inhibitor Therapy: A Precision Medicine Approach to Overcome Drug Resistance in Desensitization.

    J. Driscoll,1 S. Tremblay,1 P. Brailey,1 A. Girnita,1 R. Alloway,1 B. Aronow,2 H. Singh,2 E. Woodle.2

    1U of Cincinnati, Cincinnati, OH; 2Cincinnati Children's, Cincinnati, OH

    Purpose: Bone marrow niche-resident plasma cells (BMNRPCs) exhibit variable sensitivity to proteasome inhibitor (PI) therapy. Here, we characterized alterations in the gene and protein expression…
  • 2017 American Transplant Congress

    Inflammatory Conditions Dictate the Effect of MSC on B Cell Function.

    F. Luk,1 L. Carreras-Planella,2 S. Korevaar,1 S. de Witte,1 F. Borràs,2 M. Betjes,1 C. Baan,1 M. Hoogduijn,1 M. Franquesa.1,2

    1Nephrology and Transplantation, Dept. of Internal Medicine, Erasmus MC, University Medical Center, Rotterdam, Netherlands; 2Nephrology and Transplantation, Institut d'Investigació Germans Trias i Pujol, Badalona, Spain

    The immunomodulatory capacity of mesenchymal stem or stromal cells (MSC) makes them a promising therapeutic tool for immune disease and organ transplantation. The effects of…
  • 2017 American Transplant Congress

    Hypogammaglobulinemia in Pediatric Heart Transplant Candidates Is Not Corrected by Transplantation.

    R. Madan,1 R. Penkert,2 J. Dara,1 J. Lamour,1 B. Herold,1 J. Hurwitz.2

    1Pediatrics, Albert Einstein College of Medicine and The Children's Hospital at Montefiore, Bronx, NY; 2Infectious Diseases, St Jude Children's Research Hospital, Memphis, TN

    Introduction: Hypogammaglobulinemia (HG) is associated with poor outcomes in adult heart transplant recipients but is not well studied in pediatric recipients. We therefore investigated longitudinal…
  • 2017 American Transplant Congress

    Antibody Mapping by Protein Microarray Revealed a Unique Repertoire in Lung Transplant Recipients That Developed Chronic Lung Allograft Dysfunction.

    D. Nayak,1 K. Garcia,2 P. Pirrotte,2 R. Hachem,3 R. Bremner,1 M. Smith,1 T. Mohanakumar.1

    1Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ; 2Translational Genomics Research Institute, Phoenix, AZ; 3Washington University, St. Louis, MO

    Background: Development of chronic lung allograft dysfunction (CLAD) limits long-term success from lung transplantation (LTx). Elicitation of de novo antibody (Ab) to mismatched donor HLA…
  • 2017 American Transplant Congress

    Percentage of CD19+ B Cells as a Predictor of Acute Antibody-Mediated Rejection After Administration of Rituximab in ABO-Incompatible Kidney Transplantation.

    T. Hirose, D. Iwami, K. Hotta, H. Sasaki, H. Higuchi, N. Shinohara.

    Urology, Hokkaido University, Sapporo, Japan

    [Introduction] Administration of rituximab to ABO-incompatible kidney transplant (ABOi-KTx) recipients is recognized as effective and safe. A single dose of 375 mg/m2 rituximab is generally…
  • 2017 American Transplant Congress

    A Novel Role for MyD88 Signaling Downstream from Toll-Like Receptors in B Cells Responding to Blood Group Antigens.

    H. Sakai, Y. Tanaka, H. Ohdan.

    Hiroshima University, Hiroshima, Japan

    [Introduction]Although there is some empirical evidence that severe infectious complications provoke refractory AMR following ABO-incompatible transplantations (ABOi-Tx), its mechanism remains unclear. Here, we investigated a…
  • 2017 American Transplant Congress

    TFR:TFH Cell Ratio Correlates with Anti-Donor Germinal Center Reactivity and Donor-Specific Antibody Formation Following Transplantation.

    G. La Muraglia II, M. Ford, I. Badell.

    Emory Transplant Center, Emory University School of Medicine, Atlanta, GA

    Kidney transplantation is the treatment of choice for patients with end-stage renal disease. Although short-term outcomes are excellent, long-term allograft survival rates remain inadequate. It…
  • 2017 American Transplant Congress

    Outcome of ABO-Incompatible Kidney Transplantation After Stratified Desensitization.

    K. Nanmoku, A. Kurosawa, T. Kubo, T. Shinzato, T. Shimizu, T. Kimura, T. Yagisawa.

    Surgical Branch, Institute of Kidney Diseases, Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan

    Background. Plasmapheresis for antibody removal and rituximab for antibody production suppression are performed for desensitization against ABO-incompatible kidney transplantation. We evaluated clinical outcome for optimizing…
  • 2017 American Transplant Congress

    Expansion, Function and Clonotypic Analysis of Human Alloreactive Treg Stimulated with Different Dendritic Cell Populations or CD40L-Stimulated B Cells.

    H. Zhang,1 Y. Zhao,1 Q. Tang,3 A. Thomson.1,2

    1Thomas E. Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA; 2Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA; 3Department of Surgery, UCSF, San Francisco, CA

    Purpose:In order to establish a protocol to generate large numbers of human alloantigen-reactive regulatory T cells (arTreg) with potent allospecific suppressive capacity for therapeutic application,…
  • « Previous Page
  • 1
  • …
  • 22
  • 23
  • 24
  • 25
  • 26
  • …
  • 35
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences